2021: A Unique World Hepatitis Day
Hepatitis Can't Wait! VIDC is committed to eliminating viral hepatitis by 2030. Find out how you can join our fight.
top of page
COVID-19 & Sports
COVID-19 & Sports
COVID-19 & Sports
Published Work
From observational studies to clinical trials, the VIDC research team shares our findings with the medical community at international conferences.
​
Visit us at an upcoming conference >
Search
- Feb 28, 2020
Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users
Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the GRAND PLAN study Presented at the...
- Feb 28, 2020
Sofosbuvir/velpatasvir (S/V) for the treatment of chronic HCV in active drug users: the CHIME study
Presented at the Canadian Liver Meeting. February 28- March 1, Montreal, Canada, 2020.
- Feb 28, 2020
Overdose events among active drug users successfully treated for HCV: the impact of homelessness.
Presented at the Canadian Liver Meeting. February 28- March 1, Montreal, Canada, 2020.
- Feb 11, 2020
Glecaprevir/pibrentasvir+sofosbuvir: An optimal retreatment strategy in the setting of HCV NS5A ...
Some individuals do not achieve a cure of their hepatitis C virus (HCV) infection due to non-adherence or resistance associated substitution
- Dec 16, 2019
Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C
Advances in hepatitis C virus (HCV) treatment led to the development of highly effective all oral direct acting antiviral regimens.
- Nov 8, 2019
Effectiveness of sofosbuvir/velpatasvir and elbasvir/grazoprevir for the treatment of HCV genotype 1
Effectiveness of sofosbuvir/velpatasvir and elbasvir/grazoprevir for the treatment of HCV genotype 1 infection in a real-world cohort...
- Nov 8, 2019
Long-term follow-up of people who use drugs (PWUD) following successful HCV therapy...
Long-term follow-up of people who use drugs (PWUD) following successful HCV therapy: drug use patterns and maintenance of cure Presented...
- Oct 14, 2019
Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C
Concerns about reinfection may be limiting HCV treatment uptake among people who use drugs (PWUD), with rates of 17.1/100 person-years in...
- Jul 17, 2018
Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject
Vancouver’s Downtown Eastside (DTES) faces the interrelated challenges of poverty, homelessness, mental health, addiction, and medical issue
bottom of page